Apple Health Outcome
10 compoundsin Regimen’s catalog are configured to track deep sleep via Apple Health. Each one shows the dose range, listed benefits, and every outcome it’s set up to monitor. Tap through to plan a dose with the free reconstitution calculator.
Deep sleep (also called slow-wave sleep, SWS, or N3) is the stage during which the pituitary releases its largest pulses of growth hormone. It is concentrated in the first third of the night and accounts for roughly 15–25% of total sleep in young adults, declining with age. The relationship is bidirectional: GH amplifies slow-wave activity, and slow-wave activity drives GH release.
This is the architectural target of GH secretagogues. CJC-1295/ipamorelin, MK-677, and tesamorelin all amplify the GH pulse pattern, and users frequently report subjective improvements in deep sleep within the first 1–2 weeks. Objective polysomnography data is limited but consistent with the subjective reports.
For users whose deep-sleep percentage on Apple Watch is below 15% of total sleep, GH secretagogues are one of the more mechanistically coherent peptide interventions — alongside fixing sleep hygiene and addressing untreated sleep apnea.
Anchor citation: Van Cauter E et al.. Reciprocal interactions between the GH axis and sleep. Growth Hormone & IGF Research, 2004.
10 compounds
GHRH / GHRP Combination
A synergistic growth hormone releasing combination for body composition, sleep, and recovery.
Tracks
Tracks
Tracks
GHRH (1-29) Analog
Synthetic analog of the first 29 amino acids of growth hormone–releasing hormone. Stimulates the pituitary to release endogenous GH in pulses, preserving the natural feedback loop and avoiding suppressed pituitary axis seen with exogenous HGH.
Tracks
Recombinant Human Growth Hormone
Recombinant DNA-derived 191-amino-acid growth hormone identical to endogenous human somatropin. FDA-approved for clinical GH deficiency (adult and pediatric); used off-label for body composition, recovery, and anti-aging. Direct hormone replacement — bypasses the pituitary axis (unlike Sermorelin/Tesamorelin).
Tracks
Tracks
Tracks
Ghrelin Receptor GH Secretagogue
A synthetic hexapeptide that binds the ghrelin/GHS-R1a receptor to stimulate pulsatile growth hormone release from the anterior pituitary. Researched for GH deficiency, cachexia, and tissue-protective effects; also a potent appetite stimulant.
Tracks
Oral Ghrelin Mimetic / GH Secretagogue
An orally bioavailable, non-peptide ghrelin receptor agonist that produces sustained increases in GH and IGF-1 with once-daily dosing. Taken as a capsule — no reconstitution needed. Studied for sarcopenia, GH deficiency, and recovery support.
Tracks
Next-gen Ghrelin Receptor Agonist (research)
A research-grade non-peptide ghrelin receptor (GHS-R1a) agonist developed as a successor to MK-677. Vendor and analog modeling describe higher receptor affinity and longer half-life, but human clinical data are not yet published.
Tracks
MK-677 has the strongest published data — a 2-year Annals of Internal Medicine trial reported improved subjective sleep with elevated IGF-1. CJC-1295/ipamorelin combinations are anecdotally similar but with less rigorous published evidence. Tesamorelin has data in HIV-lipodystrophy populations and operates on the same axis.
Subjective deepening of sleep typically appears within the first 1–2 weeks. Apple Watch deep-sleep percentages can take 2–4 weeks to show consistent change because of night-to-night variability. The 30-day sparkline in Regimen smooths this and makes the trajectory clearer than any single night.
Related reading
Best peptide tracker app in 2026
An honest multi-protocol comparison of Regimen, PeptIQ, Shotsy, MeAgain, and the GLP-1 calculator apps.
Other outcomes